DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma - PubMed
5 days ago
- #immunotherapy
- #DNA repair genes
- #pancreatic cancer
- The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Plasma sequencing identified concurrent mutations in DNA damage repair genes (BRCA1, POLE, ATM, FANCA) in 10.4% of patients.
- Patients with two or more mutations in these genes had significantly better overall survival with immunotherapy (26.2 vs. 9.7 months).
- Partial response was observed in 63.64% of patients with concurrent DNA damage repair gene mutations in the immunotherapy arm.
- The study highlights an actionable subgroup of mPDAC that may benefit from immunotherapy beyond mismatch repair deficiency.